TechsoMed ^{For Profit}

TechsoMed is a medical technology company that has developed BioTrace™, the world's first and only image analysis system that predicts and visualizes the 24-hour post-treatment ablation morphology in real-time. The system interfaces with commercial ultrasound imaging systems to track the tissue's unique "biological signature" when responding to heat during thermal ablation. This signature is used to predict and visualize the post 24-hour thermal effect in real-time, optimizing the surgeon's level of control and accuracy during the procedure, to minimize healthy tissue damage and maximize target tissue ablation. The BioTrace™ system is a comprehensive all-around solution that affects and improves all stages of patient care, from PSM, through planning & simulation to real-time lesion imaging & efficacy analysis. The company has a team of experienced professionals and has partnerships with various investors, partners, and clinical organizations. The company has received FDA clearance for its BioTrace solution and has completed full enrollment in a pivotal US trial, evaluating its BioTraceIO software for liver ablation outcomes assessment in liver cancer patients. Contact info: Tel: +972-8-6198866, Email: info@techsomed.com, Address: Meir Weisgal 2, Rehovot, Israel.